Apellis Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
06/11/2024 04:55
* Apellis Pharmaceuticals Inc APLS.OQ reported a quarterly
adjusted loss of 46 cents per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of $-1.17. The mean expectation of
twenty analysts for the quarter was for a loss of 30 cents per
share. Wall Street expected results to range from -43 cents
to -17 cents per share.
* Revenue rose 78.3% to $196.83 million from a year ago;
analysts
expected $200.35 million.
* Apellis Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 46 cents.
* The company reported a quarterly loss of $57.45 million.
* Apellis Pharmaceuticals Inc shares had fallen by 2.7% this
quarter and lost 53.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 23.9%
in the last three months.
* In the last 30 days, four analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Apellis
Pharmaceuticals Inc is 52.00
This summary was machine generated from LSEG data November 6 at
04:54 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.30 -0.46 Missed
Jun. 30 2024 -0.32 -0.28 Beat
Mar. 31 2024 -0.47 -0.42 Beat
Dec. 31 2023 -0.69 -0.73 Missed